Interest in Nighttime Day Hospital Chemotherapy Infusions Among Gynecologic Cancer Patients (CHeMoON)

March 16, 2026 updated by: FAGOTTI ANNA, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Assessment of Interest Among Patients With Gynecologic Cancers in a Nighttime Day Hospital (DH) Service for Long-duration Chemotherapy Infusions: an Observational Study Based on an Anonymous Online Survey.

This observational study aims to assess the interest of patients with gynecologic cancers in a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions. An anonymous online survey will be distributed to eligible patients to evaluate their preferences, perceived benefits, and potential barriers related to receiving chemotherapy during nighttime hours. The results of this study will help inform the feasibility and acceptability of implementing a nighttime Day Hospital service for prolonged chemotherapy infusions.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Long-duration chemotherapy infusions are increasingly used in the treatment of gynecologic cancers. These treatments often require prolonged administration times that may extend over several hours and may affect patients' daily activities and quality of life when delivered during standard daytime hospital schedules. The implementation of a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions could represent an alternative organizational model aimed at improving patient convenience and optimizing hospital resource utilization. However, the acceptability of such a service from the patients' perspective has not been well explored.

This observational study will evaluate the interest and perceived acceptability of a nighttime Day Hospital service among patients with gynecologic cancers who may receive long-duration chemotherapy infusions. Data will be collected through an anonymous online survey administered to eligible patients. The questionnaire will explore patient preferences, potential advantages and disadvantages, logistical considerations, and willingness to receive chemotherapy during nighttime hours.

The results of this study may provide preliminary information on patient perspectives and help inform future organizational strategies for the delivery of prolonged chemotherapy infusions.

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Italy
      • Roma, Italy, 00168
        • Fondazione Policlinico Universitario A. Gemelli IRCCS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with gynecologic cancers receiving care at the participating institution who are invited to complete an anonymous online survey assessing their interest in a nighttime Day Hospital service for long-duration chemotherapy infusions.

Description

Inclusion Criteria:

  • Female patients
  • aged 18 years or older
  • Diagnosis of a gynecologic cancer
  • Receiving care at the participating institution
  • Ability to independently understand and complete complete the anonymous online survey

Exclusion Criteria:

  • Inability to access or complete the online questionnaire or difficulty with reading and writing
  • Cognitive impairment
  • Patients currently hospitalized or in emergency settings.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with gynecologic cancers
Patients affected by gynecologic cancers receiving care at the participating institution who are invited to complete an anonymous online survey assessing their interest in a nighttime Day Hospital service for long-duration chemotherapy infusions.
Behavioral: online survey
Participants will complete an anonymous online survey designed to assess their interest in a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Level of patient interest in a nighttime Day Hospital service for long-duration chemotherapy infusions
Time Frame: Baseline
Assessment of the level of interest among patients with gynecologic cancers in receiving long-duration chemotherapy infusions during nighttime hours in a Day Hospital setting, as evaluated through responses to an anonymous online survey.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Investigators

  • Principal Investigator: Anna Fagotti, Fondazione Policlinico Universitario A. Gemelli, IRCCS

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 12, 2026

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

July 1, 2026

Study Registration Dates

First Submitted

March 12, 2026

First Submitted That Met QC Criteria

March 16, 2026

First Posted (Actual)

March 19, 2026

Study Record Updates

Last Update Posted (Actual)

March 19, 2026

Last Update Submitted That Met QC Criteria

March 16, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 26945
  • Study ID 26945 (Other Identifier: CET Lazio Area 3)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gynecologic Cancers

Clinical Trials on online survey

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe